Visit us at Booth #31 | June 10-13 | Rotterdam, Netherlands
Join us at European Association for Cancer Research (EACR 24) to hear how to reduce the challenges with consistency, supply, and scalability in your research and therapeutic programs with our high-quality reagents, immunoassays, automated protein analytics, and multiomics solutions.
We are committed to supporting your cancer research from target discovery to cell therapy development.
Check out our presence at EACR
Featured Resources
Webinar: MultiTAA-Specific T Cells: A Novel Treatment for Cancer
One of the major limitations of engineered T cell therapies for treating cancer, such as CAR-T and TCR, is their ability to target only a single antigen. Although these therapies can initially provide a significant response, these treatments can eventually lead to tumor resistance through antigen escape mechanisms.
In this webinar, Juan F. Vera presents a novel technique for targeting up to six antigens, providing a more potent and durable anti-tumor response, without the need for genetic modification. The Multi-Antigen Targeted (MultiTAA) cell therapy approach is currently being utilized in clinical trials for treatment of hematological malignancies, displaying high safety and efficacy. During Juan's presentation, you will gain insight into:
- The enhanced patient outcomes achieved by targeting multiple antigens through MultiTAA T cell therapies
- Notable process improvements carried out by Marker Therapeutics resulting in reduced manufacturing time, decreased contamination risks, and significant cost savings
- Applications of MultiTAA in ongoing clinical trials to treat patients with acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL)
The Role of Proteomics in Early Cancer Detection- A Look at Six Core Benefits
Recent advances in proteomic-based technologies have enabled the identification of potential biomarkers that can be used to better detect cancers and track tumor progression.
As cancer progresses, changes in protein profiles and differences in protein distribution (both in tissues and bodily fluids) can be examined through the quantitative profiling of numerous proteins. That’s where proteomic data can deliver substantial value. By adding proteomic algorithmic signature data, you can increase cancer assay specificity and sensitivity, and improve the probability of earlier detection.
Studies that profile proteomic patterns present new opportunities for the development of novel, highly sensitive diagnostic tools for early cancer detection. Explore the 6 core benefits of incorporating proteomics in early cancer biomarker detection.
Cancer Metabolism Brochure
Cancer cells generate a large proportion of their ATP by metabolizing glucose via aerobic glycolysis, as opposed to mostly through oxidative phosphorylation (OXPHOS) in normal cells. Malignant transformation and altered metabolism go hand in hand, because the rapid increase in proliferation places increased demand on metabolic processes that cannot be met by conventional cellular metabolism. Cancer requires three crucial metabolic adaptations for rapid cell proliferation and survival: increased ATP production to fuel their high energy needs; increased biosynthesis of the three major classes of cellular building blocks, that is proteins, lipids, and nucleic acids; and an adapted redox system to counteract the increase in oxidative stress.